文献速递药物不良反应与药物警戒

左旋咪唑不良反应随适应症与误用而变化:系统药物警戒研究

Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study.
PubMed 文献 · Br J Clin Pharmacol · 2021-09-15

本研究基于WHO药物警戒数据库VigiBase,提取左旋咪唑相关不良反应报告1763例,采用不比例分析比较其精神、肝胆、血管、神经、血液等系统不良反应报告频率。结果显示多数不良反应发生于免疫调节适应症及多剂量方案,单剂量驱虫治疗安全性良好。

要点

  • 左旋咪唑相关不良反应多发生于免疫调节适应症和多剂量方案。
  • 与其它药物相比,左旋咪唑更常报告脑病、血管炎、神经病变等严重反应。
  • 单剂量用于驱虫时安全性较好。

核心结论

  • 左旋咪唑相关不良反应绝大多数涉及免疫调节适应症和多剂量方案。
  • 单剂量驱虫治疗具有较好的安全性。

研究设计与样本

  • 基于VigiBase数据库的系统药物警戒研究,提取左旋咪唑相关不良反应报告1763例。
  • 采用不比例分析比较左旋咪唑与其他药物在多个系统的不良反应报告频率。
  • 次要分析比较左旋咪唑与甲苯达唑之间以及不同使用类型之间的不良反应频率。

主要发现

  • 精神障碍报告比值比1.4(95%CI 1.2-2.6),肝胆障碍2.4(1.9-4.3)。
  • 血管炎报告比值比6.5(95%CI 4.1-10.6),脑病22.5(17.4-39.9),神经病变4.3(2.9-7.1)。
  • 血液学障碍、轻度皮疹和肌肉骨骼障碍在左旋咪唑中报告频率也高于其他药物。
  • 大多数左旋咪唑相关不良反应发生于非抗感染适应症给药时。

关键数值与推荐

  • 精神障碍报告比值比1.4(95%CI 1.2-2.6)。
  • 肝胆障碍报告比值比2.4(95%CI 1.9-4.3)。
  • 血管炎报告比值比6.5(95%CI 4.1-10.6)。
  • 脑病报告比值比22.5(95%CI 17.4-39.9)。
  • 神经病变报告比值比4.3(95%CI 2.9-7.1)。

临床怎么用

  • 临床应严格限制左旋咪唑的免疫调节适应症使用,优先选择更安全的替代方案。
  • 使用左旋咪唑期间应监测精神、肝胆、血管、神经及血液系统不良反应。
  • 单剂量左旋咪唑用于驱虫治疗时安全性较好,但仍需注意个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Levamisole was initially prescribed for the treatment of intestinal worms. Because of immunomodulatory properties, levamisole has been used in inflammatory pathologies and in cancers in association with 5-fluorouracil. Levamisole is misused as a cocaine adulterant. Post-marketing reports have implicated levamisole in the occurrence of adverse drug reactions (ADRs) and its use is now limited in Europe and North America. In contrast, all other parts of the World continue to use single-dose levamisole as an anthelmintic. The aim of this study was to identify ADRs reported after levamisole exposure in VigiBase, the World Health Organisation's pharmacovigilance database, and analyse their frequency compared to other drugs and according to levamisole type of use. METHODS: All levamisole-related ADRs were extracted from VigiBase. Disproportionality analyses were conducted to investigate psychiatric, hepatobiliary, renal, vascular, nervous, blood, skin, cardiac, musculoskeletal and general ADRs associated with levamisole and other drugs exposure. In secondary analyses, we compared the frequency of ADRs between levamisole and mebendazole and between levamisole type of use. RESULTS: Among the 1763 levamisole-related ADRs identified, psychiatric disorders (reporting odds ratio with 95% confidence intervals: 1.4 [1.2-2.6]), hepatobiliary disorders (2.4 [1.9-4.3]), vasculitis (6.5 [4.1-10.6]), encephalopathy (22.5 [17.4-39.9]), neuropathy (4.3 [2.9-7.1]), haematological disorders, mild rashes and musculoskeletal disorders were more frequently reported with levamisole than with other drug. The majority of levamisole-related ADRs occurred when the drug was administrated for a non-anti-infectious indication. CONCLUSION: The great majority of the levamisole-related ADRs concerned its immunomodulatory indication and multiple-dose regimen. Our results suggest that single-dose treatments for anthelmintic action have a good safety profile.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Campillo JT, Eiden C, Boussinesq M, et al. Adverse reactions with levamisole vary according to its indications and misuse: A systematic pharmacovigilance study. Br J Clin Pharmacol. 2021. PMID: 34390273. doi:10.1111/bcp.15037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。